|
The manufacturer was notified of an explant involving a perceval plus heart valve.The following provides a summary of all information currently available to the manufacturer from the healthcare facility.On (b)(6) 2026, the patient underwent coronary artery bypass grafting (cabg) and aortic valve replacement (avr) with a perceval plus size xl bioprosthesis.Subsequently, the patient was evaluated in the postoperative period due to the development of acute pulmonary edema.Echocardiographic examination revealed that the implanted perceval plus valve had become displaced from its original position.Consequently, the patient underwent re-operation on (b)(6) 2026.During the intraoperative assessment, the perceval valve was explanted and examined for potential reimplantation.The explanted valve was attempted to be collapsed and difficulties were encountered as they were not able to fit the valve properly into the delivery system.Subsequent inspection revealed a deformation in the inflow section of the valve.As a result, the valve was replaced with another new perceval plus size xl valve.
|
|
The manufacturing and material records for the device involved in this event, as they pertain to the reported issue, were retrieved and reviewed by the manufacturer¿s quality engineering.The results confirmed that this prosthesis satisfied all required material, visual, and performance standards at the time of manufacture and release.A follow-up report will be submitted upon completion of device investigation and/or availability of additional information.
|